This bill amends the Federal Food, Drug, and Cosmetic Act to broaden the scope of molecularly targeted pediatric cancer investigations and to tighten how these studies are designed and required. It also extends the Rare Pediatric Disease Priority Review Voucher program to September 30, 2030 and adjusts related user fees, with a requirement for federal agencies to issue guidance and for Congress to receive ongoing oversight.
The changes would apply to applications submitted three years after enactment, aligning incentives with pediatric labeling efforts while adding new safeguards and timelines.
At a Glance
What It Does
It amends 505B(a)(3) to define molecularly targeted pediatric cancer investigations and adds design requirements, tying pediatric data to dosing, safety, and preliminary efficacy needed for labeling. It also clarifies when such investigations may be required and introduces a conforming framework across related sections.
Who It Affects
Sponsors applying for pediatric cancer indications under 505(b) and 351(a), the FDA (CDER/FDI), clinical trial networks, and pediatric patients who would benefit from more robust pediatric data and approved targeted therapies.
Why It Matters
By mandating clinically meaningful pediatric data and clarifying when such studies are required, the bill aims to accelerate availability of targeted pediatric cancer treatments while improving safety and labeling for children.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Mikaela Naylon Give Kids a Chance Act of 2025 makes a targeted adjustment to how the FDA evaluates cancer drugs for pediatric use. It changes the way molecularly targeted pediatric cancer investigations are described under the FD&C Act and adds specific requirements for how those studies should be designed to generate meaningful data for children.
In practice, this means sponsors submitting pediatric cancer applications would need to show dosing, safety, and early efficacy data tailored to children, with the aim of informing pediatric labeling. The bill specifies that investigations can be required only in particular circumstances, such as when a drug has a single new active ingredient or when a combination is involved under strict conditions tied to adult approvals and molecular targets relevant to pediatric cancers.
In addition, the act would grant the FDA authority to determine whether the amended requirements apply to a given application and to align it with existing pathways under 505(b) and the Public Health Service Act. A separate element extends the Rare Pediatric Disease Priority Review Voucher program through September 30, 2030, and alters related user-fee arrangements to reflect voucher use.
The bill also requires a draft FDA guidance within 12 months of enactment, to be finalized within a year after the public comment period. Finally, it sets up reporting and oversight—Congressional and GAO—to assess implementation and voucher effectiveness.
The substantive provisions would begin applying to applications submitted three years after enactment, allowing time for industry and regulators to adapt. Overall, the bill seeks to speed up pediatric, targeted-cancer drug development with stronger data requirements while maintaining safety and accountability.
The Five Things You Need to Know
The bill redefines molecularly targeted pediatric cancer investigations under 505B(a)(3), adding new subparagraphs and conditions for what qualifies.
Investigations must be designed to yield clinically meaningful pediatric data, including age-appropriate dosing, safety, and preliminary efficacy to inform labeling.
The requirement to conduct such investigations is limited to two scenarios: a single new active ingredient, or a defined combination where the ingredients have specific adult- cancer approvals and a relevant pediatric molecular target.
The Secretary must issue draft implementation guidance within 12 months and finalize it within 12 months after the comment period on the draft.
The act extends the Rare Pediatric Disease Priority Review Voucher program to Sept. 30, 2030, and changes related user-fee rules, plus mandates GAO oversight and a study of voucher effectiveness.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This Act may be cited as the Mikaela Naylon Give Kids a Chance Act of 2025, establishing the overall purpose and scope for the amendments that follow.
Molecularly targeted pediatric cancer investigations defined and required design
Section 2(a) redesignates and adds the definition of a molecularly targeted pediatric cancer investigation under 505B(a)(3), specifying when such investigations count and what constitutes the activity being investigated. Section 2(b) imposes design requirements to ensure the data gathered in these pediatric investigations are clinically meaningful, including appropriate age formulations, dosing regimens, safety assessments, and early efficacy signals intended to inform pediatric labeling.
Limitation on when investigations may be required
This section sets practical limits on triggering pediatric investigations. It allows requirements only when there is either a single new active ingredient or a specified combination of actives, where each ingredient appears in a product with adult cancer approvals and where the combination targets a molecular mechanism substantially relevant to pediatric cancer.
Guidance and applicability
The Secretary must issue a draft guidance within 12 months of enactment and finalize it within 12 months after the close of the comment period. The amendments apply to applications submitted on or after a date three years after enactment for applications under 505(b) and 351(a), coordinating timing with the broader regulatory framework.
Extension of Rare Pediatric Disease Priority Review Vouchers
Section 3 extends the voucher program to September 30, 2030 and modifies related user fees, clarifying how vouchers are paid for and used. It also requires a GAO study evaluating voucher effectiveness and imposes reporting requirements to Congress on implementation and impact.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Drug sponsors pursuing pediatric cancer indications gain clearer pathways to develop age-appropriate data and labeling.
- Pediatric patients and families benefit from potentially faster access to targeted, labeled pediatric cancer therapies with safer dosing and efficacy information.
- FDA reviewers and CDER staff gain clearer guidance and predictable processes for evaluating pediatric cancer investigations.
- Academic medical centers and pediatric oncology trial networks obtain clearer criteria and opportunities to participate in well-defined pediatric studies.
- Payers and health systems may benefit from more robust pediatric labeling that supports safer, more effective pediatric use.
Who Bears the Cost
- Sponsors of pediatric cancer investigations face greater design burdens, longer development timelines, and increased data generation requirements.
- Small biotech firms with limited resources may bear higher upfront costs for pediatric data generation and trial execution.
- Clinical trial sites and CROs conducting pediatric studies may see increased workload and regulatory monitoring.
- FDA staff must develop, publish, and maintain guidance and oversight activities, which require budget and staffing.
Key Issues
The Core Tension
The central dilemma is balancing the urgency of delivering pediatric-targeted cancer therapies with the need for rigorous, child-specific data—and doing so in a way that remains workable for sponsors while preserving the FDA’s ability to ensure safety and efficacy.
The bill creates a tension between accelerating access to potentially life-saving pediatric cancer therapies and ensuring that pediatric data are robust and appropriate for children’s unique physiology. The new design requirements impose higher initial data-generation obligations and stricter formatting of pediatric studies, which could slow early-stage development or increase trial complexity.
At the same time, extending the voucher program through 2030 aims to sustain incentives for developers, but it also concentrates attention on the efficacy of vouchers and their real-world impact on pediatric innovation. The timing provisions—especially the three-year applicability window—are intended to give industry time to adapt, but may delay some applications that would otherwise have proceeded sooner.
Finally, the reliance on guidance development and GAO oversight creates a regulatory feedback loop that could be delayed by administrative review processes or changing policy priorities.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.